Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
- 1 June 1988
- Vol. 29 (6) , 835-837
- https://doi.org/10.1136/gut.29.6.835
Abstract
One hundred and sixty four patients with ulcerative colitis in remission were entered into a double blind, double dummy trial comparing olsalazine 500 mg bd and sulphasalazine 1 g bd. Clinical examination, sigmoidoscopy and rectal biopsy were performed at 0, three, and six months. Sixteen of 82 (19.5%) patients relapsed on olsalazine and 10/82 (12.2%) relapsed on sulphasalazine. The difference was not statistically significant (p = 0.1632). Adverse events were minor and were similar in both groups. No haematological or biochemical abnormalities were detected. Thus, olsalazine is as effective as sulphasalazine for preventing a relapse of ulcerative colitis.This publication has 12 references indexed in Scilit:
- Effects of olsalazine in the jejunum of the rat.Gut, 1987
- Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.Gut, 1986
- Azodisal sodium in the treatment of ulcerative colitisGastroenterology, 1986
- Olsalazine in active ulcerative colitis.BMJ, 1985
- SulfasalazineDigestive Diseases and Sciences, 1983
- Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut, 1982
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977
- Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's diseaseClinical Pharmacology & Therapeutics, 1975
- A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)Gut, 1973
- Cortisone in Ulcerative ColitisBMJ, 1955